ClearPoint Neuro, Inc.
NASDAQ:CLPTMedical - Devices
+$0.89 today
- Market cap
- $247.14M
- Beta
- 1.31
- P/E (TTM)
- -18.0
- EPS (TTM)
- -$0.98
Volume 0.64M
Average 0.67M
CLPT Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
ClearPoint Neuro, Inc.NASDAQ: CLPT
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization growth accelerates
Q1 FY2026 depreciation & amortization of $1.11M rose 233.2% year over year, ahead of the +64.4% change in trailing-twelve-month depreciation & amortization. Over 3 fiscal years it compounded at +8.1% a year.
Context
- Depreciation & amortization amounted to 2.7% of revenue in FY2025, down 3.4 pp from a year earlier.
- Depreciation & amortization increased in 2 of the last 3 fiscal years.
What to watch
Whether quarterly growth of +233.2% holds above the trailing-twelve-month pace of +64.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 982K USD
- Year-over-year change
- -48.4%
- 4-year CAGR
- +9.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 982K | -48.4% |
| FY2024 | 2024-12-31 | 1.9M | +25.7% |
| FY2023 | 2023-12-31 | 1.51M | +94.9% |
| FY2022 | 2022-12-31 | 777K | +12.3% |
| FY2021 | 2021-12-31 | 692K | — |
Depreciation & Amortization vs competitors
How CLPT compares with its peers on the latest reported figures
- Peers report in different currencies, so depreciation & amortization is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +64.4% is the 2nd highest of 10, against a peer median of -0.7%.
- Depreciation & amortization amounts to 4.3% of revenue for CLPT, versus a peer median of 5.7%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $136.43M USD | +43.1% | +37.4% | 16.5% | |
| LTM Mar 2026 | CA$56.2M CAD | -0.2% | +5.9% | 6.0% | |
| LTM Mar 2026 | $39.5M USD | -9.6% | -6.6% | 5.5% | |
| LTM Apr 2026 | $27.1M USD | -0.7% | -6.8% | 3.2% | |
| LTM Mar 2026 | $11.9M USD | +9.1% | +28.4% | 5.8% | |
| LTM Mar 2026 | $10.99M USD | -30.6% | -51.5% | 12.7% | |
| LTM Mar 2026 | $8.15M USD | +78.5% | -7.6% | 4.0% | |
| LTM Mar 2026 | $1.76M USD | +64.4% | +8.1% | 4.3% | |
| LTM Mar 2026 | $1.28M USD | -96.1% | -67.7% | 0.6% | |
| LTM Mar 2026 | $179K USD | -14.4% | -13.2% | — | |
| Peer median (excluding CLPT) | — | -0.7% | -6.8% | 5.7% | |
Competitors are the stored peer set for CLPT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (14.41M) | (16.43M) | (22.09M) | (18.91M) | (25.54M) |
| Depreciation & Amortization | 692K | 777K | 1.51M | 1.9M | 982K |
| Deferred Income Tax | 202K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 2.08M | 4.13M | 6.08M | 6.91M | 8.18M |
| Change in Working Capital | (1.68M) | (4.29M) | (1.4M) | 1.4M | (9.81M) |
| Accounts Receivables | 627K | (211K) | (1.8M) | (1.21M) | (268K) |
| Inventory | (1.71M) | (4.42M) | 1.25M | 743K | (103K) |
| Accounts Payables | (762K) | 1.59M | 0 | 3.11M | (7.52M) |
| Other Working Capital | 165K | (1.25M) | (846K) | (1.24M) | (1.92M) |
| Other Non-Cash Items | 425K | 3.78M | 2.18M | (245K) | 2.27M |
| Operating Cash Flow | (12.7M) | (16.17M) | (13.72M) | (8.95M) | (23.93M) |
| Capital Expenditures | (168K) | (253K) | (717K) | (275K) | (522K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 1.14M |
| Purchases of Investments | 0 | (21.59M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 12M | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 9.67M | 0 | 0 |
| Investing Cash Flow | (168K) | (10.74M) | 8.95M | (275K) | 615K |
| Debt Repayment | 0 | 0 | 0 | (10M) | 48.09M |
| Common Stock Issued | 46.79M | 745K | 0 | 16.15M | 3.95M |
| Common Stock Repurchased | 0 | 0 | (210K) | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 90K | (336K) | 506K | 40K | (1.86M) |
| Financing Cash Flow | 46.88M | 409K | 296K | 6.19M | 50.18M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 34.01M | (26.49M) | (4.48M) | (3.04M) | 26.87M |
| Free Cash Flow | (12.87M) | (16.42M) | (14.44M) | (9.23M) | (24.45M) |
ClearPoint Neuro, Inc.
NASDAQ:CLPT
Intrinsic Alpha fair value
Locked
Current Price
$7.71
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.